FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/11/096758 [Registered on: 03/11/2025] Trial Registered Prospectively
Last Modified On: 01/11/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Randomized Controlled Trial to evaluate the efficacy of Draksha syrup in Vibandha in children ( 2-6 years) with reference to Functional Constipation. 
Scientific Title of Study   Randomized Controlled Trial to evaluate the efficacy of Draksha syrup in Vibandha in children ( 2-6 years) with reference to Functional Constipation. 
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  ARBAZ ISAQ SHAIKH 
Designation  PG Resident  
Affiliation  PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON 
Address  PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON KHANDOBANAGAR, AKHEGAON ROAD SHEVGAON, DIST. AHMEDNAGAR MH
PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON KHANDOBANAGAR, AKHEGAON ROAD SHEVGAON, DIST. AHMEDNAGAR MH
Ahmadnagar
MAHARASHTRA
414502
India 
Phone  842131731  
Fax    
Email  arbaz_shaikh49@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Ravindra Dhanwade 
Designation  Associate Professor  
Affiliation  PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON 
Address  PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON KHANDOBANAGAR, AKHEGAON ROAD SHEVGAON, DIST. AHMEDNAGAR MH
PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON KHANDOBANAGAR, AKHEGAON ROAD SHEVGAON, DIST. AHMEDNAGAR MH
Ahmadnagar
MAHARASHTRA
414502
India 
Phone  7620055444  
Fax    
Email  dhanwaderavi7@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Ravindra Dhanwade 
Designation  Associate Professor  
Affiliation  PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON 
Address  PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON KHANDOBANAGAR, AKHEGAON ROAD SHEVGAON, DIST. AHMEDNAGAR MH
PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON KHANDOBANAGAR, AKHEGAON ROAD SHEVGAON, DIST. AHMEDNAGAR MH
Ahmadnagar
MAHARASHTRA
414502
India 
Phone  7620055444  
Fax    
Email  dhanwaderavi7@gmail.com  
 
Source of Monetary or Material Support  
PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON KHANDOBANAGAR, AKHEGAON ROAD SHEVGAON, DIST. AHMEDNAGAR MAHARASHTRA INDIA - 414502 
 
Primary Sponsor  
Name  Dr ARBAZ ISAQ SHAIKH  
Address  PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr ARBAZ ISAQ SHAIKH   PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON  Pediatric OPD PMTs AYURVED COLLEGE AND SHRI EKNATH AYURVED RUGNALYA SHEVGAON KHANDOBANAGAR, AKHEGAON ROAD SHEVGAON, DIST. AHMEDNAGAR MH
Ahmadnagar
MAHARASHTRA 
8421317317

arbaz_shaikh49@yahoo.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethical Committe PMTs Ayurved College, Shevgaon  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:K590||Constipation. Ayurveda Condition: VIBANDHA,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Comparator Arm (Non Ayurveda)DrugOther than Classical(1) Medicine Name: LACTULOSE SYRUP , Reference: NA, Route: Oral, Dosage Form: Sharkara/ Syrup, Dose: 10(ml), Frequency: hs, Bhaishajya Kal: Adhobhakta, Duration: 07 Days, anupAna/sahapAna: No, Additional Information: -
2Comparator Arm (Non Ayurveda)Drug-
3Intervention ArmDrugClassical(1) Medicine Name: DRAKSHA SYRUP , Reference: Bhavprakash Nighantu , Route: Oral, Dosage Form: Sharkara/ Syrup, Dose: 05(ml), Frequency: hs, Bhaishajya Kal: Adhobhakta, Duration: 07 Days, anupAna/sahapAna: No, Additional Information: -
 
Inclusion Criteria  
Age From  2.00 Year(s)
Age To  6.00 Year(s)
Gender  Both 
Details  1. Patient age group 2-6 years irrespective of sex, religion and economical status
2.Children fulfilling the ROM III criteria30 or patient presenting sign and symptoms of vibandha.
3.Parents/ Guardians of the child willing to participate in clinical trial/study with written consent.  
 
ExclusionCriteria 
Details  1. Patients having Constipation due to severe illness related to Anorectal Conditions and organic disorders like Hirschsprung disease.
2. Patients with Rectal Prolapse, IBD, Malignancy, endocrinal disease etc or any other systemic illness.
3. Patient on any other long-term medications.
4. Patient known case of Neuromuscular disease like cerebral palsy 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   On-site computer system 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
DRAKSHA SYRUP is effective in Vibhandha in children within 7 days

That is, the main efficacy outcome used for sample size estimation is the mean change in spontaneous bowel movements per week from baseline to day 7.  
Follow up will be done on 0 , 3 and 7 day and outcome will be recorded. 
 
Secondary Outcome  
Outcome  TimePoints 
LACTULOSE SYRUP is effective in Vibhandha in children   Patient will be assessed on 0, 3 & 7 th day  
 
Target Sample Size   Total Sample Size="76"
Sample Size from India="76" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   13/11/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Sushrutacharya while explaining the digestive system of our body cited that the process of digestion occurs over time, drawing downward (the waste products), assisted by the wind (air or vata). It governs the excretion of feces, urine, semen, menstrual blood, and other substances. When aggravated, it causes severe diseases related to the bladder, rectum, and other associated areas. In Ayurveda, constipation is known as Vibandha or Badhapurish, presenting as a common issue in childhood that often causes considerable parental concern. It is characterized by difficulty in passing stools, typically associated with dry and hard stools and infrequent bowel movements, most prevalent among children aged 2 to 6 years. The causes of Vibandha in Ayurvedic perspective include factors like breastfeeding from a mother with vitiated Vata (Vata Dushita Stanya Sevana), parasitic infections (Krimi), and suppression of natural urges (Parish Vega-Vidharana), which disrupt normal digestive functions1. These disturbances lead to the accumulation of Ama (undigested or improperly digested food substances), aggravation of the Vata dosha (responsible for movement), and weakening of digestive fire (Jatharagni Mandya), culminating in the manifestation of constipation.2 If left untreated, Vibandha can result in complications such as vomiting (Chardana), depletion of bodily fluids (Rasa Kshaya), and emaciation (Karshya). Prevention strategies focus on dietary adjustments, including a high-fiber diet and adequate fluid intake, alongside promoting regular physical activity and timely bowel habits. Treatment of Vibandha involves a holistic approach in Ayurveda, aiming to eliminate causative factors (Nidan Parivarjana), enhance digestive fire (Dipan), aid in the digestion of toxins (Pachan), normalize Vata movement downward (Anulomana), and facilitate stool expulsion through procedures like Bhedana and Rechana3. Ayurveda views constipation not merely as a local issue but as a reflection of overall imbalance in the body. This perspective allows for treatments that address the root cause of Vibandha, promoting long-term health without adverse side effects. Additionally, Ayurvedic remedies are considered safe and effective alternatives for managing constipation, particularly when gentle, natural approaches are preferred. The global impact of childhood constipation is frequently underestimated, largely due to limited data availability within this age group4. Epidemiological studies use various definitions, ranging from the established Rome criteria to parent-reported proxies. A recent systematic review in pediatric populations indicated constipation prevalence ranging widely from 4% to 29.6%5. This variation in prevalence can be attributed not only to differing definitions but also to variations in symptom duration required for diagnosis, age distributions of study participants, and methods of data collection. Chronic constipation in children is when a child experiences two or more of the following symptoms for at least two months: fewer than three bowel movements per week, accidental leaking of stool more than once a week, stool getting stuck in the rectum, passing stool so large that it clogs the toilet, holding in stool on purpose, and pain during bowel movements. About 60% of children with constipation may experience overflow incontinence, where stool leaks out due to a build-up in the rectum. Most cases of constipation in children are due to holding in stool,either on purpose or without realizing it. About 2% of healthy primary school children have this condition, with boys being affected up to four times more often than girls.    
Close